A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Susana Banerjee Vasiliki Michalarea Joo Ern Ang Alvaro H Ingles Garces Andrea Biondo Ionut-Gabriel Funingana Martin Little Ruth Ruddle Florence I Raynaud Ruth Riisnaes Bora Gurel Sue Chua Nina Tunariu Joanna C Porter Toby Prout Mona Parmar Anna Zachariou Alison Turner Ben Jenkins Stuart McIntosh Ed Ainscow Anna R Minchom Juanita Lopez Johann S de Bono Robert Jones Emma C Hall Natalie Cook Bristi Basu Udai Banerji

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The dose of 12 mg/m2/q2Wk was declared the recommended phase II dose/schedule. At this dose/schedule, CT900 exhibited an acceptable side effect profile with clinical benefit in patients with high/medium α-FR expression and warrants further investigation.

Keyphrases

phase ii
high grade
clinical trial
open label
low grade
phase iii
computed tomography
image quality
dual energy
contrast enhanced
poor prognosis
study protocol
randomized controlled trial
placebo controlled